Benitec Biopharma Inc. reported its financial results for the second quarter (Q2) ended December 31, 2025. The company reported a net loss attributable to shareholders of USD 11.8 million, or USD 0.26 per basic and diluted share, for the quarter. Loss from operations for Q2 was USD 13.4 million. Benitec Biopharma ended the period with USD 189 million in cash and cash equivalents. In terms of business updates, Benitec Biopharma highlighted progress in its BB-301 clinical development program. The first four patients enrolled in Cohort 1 of the BB-301 Phase 1b/2a treatment study completed the 12-month statistical follow-up period, with all four classified as formal responders at the 12-month mark, demonstrating a durable response to the therapy. The first patient completed a 24-month follow-up, continuing to show improvements in post-swallow residue and overall dysphagic symptom burden compared to the 12-month results. An update on interim clinical results for Cohort 2 is scheduled for mid-2026. Additionally, a meeting with the U.S. Food and Drug Administration to formalize the pivotal BB-301 study design is expected mid-year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Benitec Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-047742), on February 12, 2026, and is solely responsible for the information contained therein.